Catalyst Pharmaceuticals Inc (CN2 F) stock market data APIs
€17.0327
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Catalyst Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Prev. Close
17.0327
Open
17.0327
High
17.0327
Low
17.0327
52 wk Range
16.635-24
Market Cap
2 068 M
P/E Ratio
11.9858
Shares Outstanding
122 M
Revenue
558 M
EPS
0.11
Beta
0.846
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 558 M
- EBITDA: 281 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: 0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News
New
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell d...
Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035
We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Catalyst Pharmaceuticals, Inc. is placed sixth among them. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical comp...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Catalyst Pharmaceuticals, Inc. As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalys...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
